Literature DB >> 20609438

Immunization with a combination of ApoB and HSP60 epitopes significantly reduces early atherosclerotic lesion in Apobtm2SgyLdlrtm1Her/J mice.

Xinjie Lu1, Daxin Chen, Valeria Endresz, Min Xia, Ildiko Faludi, Katalin Burian, Andrea Szabo, Agnes Csanadi, Andras Miczak, Eva Gonczol, Vijay Kakkar.   

Abstract

OBJECTIVE: HSP60 is emerging as an immunodominant target of autoantibodies in atherosclerosis and recent studies have revealed oxLDL as a key antigen in the development of atherosclerosis. In this study, we assay whether immunizing Apobtm2SgyLdlrtm1Her/J mice with a combination of ApoB and human HSP60 peptides has an additive effect on atheroprotection compared to ApoB or HSP60 peptides applied alone by following atherosclerotic lesion development. METHODS AND
RESULTS: In this study, 2 weeks after the first immunization, Apobtm2SgyLdlrtm1Her/J mice were placed on a high-fat diet for 8 weeks followed by 2 weeks on a normal diet allowing the mice to adapt to the environment before sacrifice. High levels of ApoB and HSP60 antibodies were detectable in week 2 and week 12 following the first immunization with KLH-conjugated ApoB and HSP60 peptides either individually or in combination. Histological analyses demonstrated that mice immunized with both, ApoB and HSP60 peptides, showed the most significant reduction in atherosclerotic lesions (41.3%; p<0.001) compared to a reduction of 14.7% (p<0.05) and 21.1% (p<0.01) in mice immunized with ApoB or HSP60 peptides, respectively; control mice were immunized with either PBS or adjuvant alone. These results were further supported by significant differences in the cellular and humoral immune responses between test animals.
CONCLUSIONS: Immunization with a combination of ApoB and HSP60 peptide antigens significantly reduced early atherosclerotic lesions in the Apobtm2SgyLdlrtm1Her/J mouse model of atherosclerosis. This approach offers promise as a novel strategy for developing anti-atherosclerotic agents.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20609438     DOI: 10.1016/j.atherosclerosis.2010.06.007

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  19 in total

Review 1.  Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases.

Authors:  Kuang-Yuh Chyu; Prediman K Shah
Journal:  Ther Adv Vaccines       Date:  2014-03

2.  Heat-shock protein 60 kDa and atherogenic dyslipidemia in patients with untreated mild periodontitis: a pilot study.

Authors:  Manfredi Rizzo; Francesco Cappello; Rafael Marfil; Luigi Nibali; Antonella Marino Gammazza; Francesca Rappa; Giuseppe Bonaventura; Pablo Galindo-Moreno; Francisco O'Valle; Giovanni Zummo; Everly Conway de Macario; Alberto J L Macario; Francisco Mesa
Journal:  Cell Stress Chaperones       Date:  2012-01-04       Impact factor: 3.667

Review 3.  Vaccination to modulate atherosclerosis.

Authors:  Takayuki Kimura; Kevin Tse; Alessandro Sette; Klaus Ley
Journal:  Autoimmunity       Date:  2015-02-16       Impact factor: 2.815

4.  Comparison of epitope specificity of anti-heat shock protein 60/65 IgG type antibodies in the sera of healthy subjects, patients with coronary heart disease and inflammatory bowel disease.

Authors:  George Füst; Katalin Uray; László Bene; Ferenc Hudecz; István Karádi; Zoltán Prohászka
Journal:  Cell Stress Chaperones       Date:  2011-10-29       Impact factor: 3.667

Review 5.  Mitochondrial DAMPs and altered mitochondrial dynamics in OxLDL burden in atherosclerosis.

Authors:  Bisma Khwaja; Finosh G Thankam; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2021-01-25       Impact factor: 3.396

Review 6.  Tolerization against atherosclerosis using heat shock protein 60.

Authors:  Cecilia Wick
Journal:  Cell Stress Chaperones       Date:  2015-11-17       Impact factor: 3.667

7.  Activation of inflammatory cells and cytokines by peptide epitopes in vitro: a simple in-vitro screening assay for prioritizing them for in-vivo studies.

Authors:  Lakshmi A Mundkur; Meenakshi Varma; Hemapriya Shivanandan; Dhanush Krishna; Kiran Kumar; Xinjie Lu; Vijay V Kakkar
Journal:  Inflamm Res       Date:  2013-02-12       Impact factor: 4.575

8.  Antibody to oxidized low-density lipoprotein inhibits THP1 cells from apoptosis by suppressing NF-κB pathway activation.

Authors:  Rui Dai; Jing Dong; Weijuan Li; Yi Zhou; Wei Zhou; Wenping Zhou; Manhua Chen
Journal:  Cardiovasc Diagn Ther       Date:  2019-08

9.  Inverse association of ApoB and HSP60 antibodies with coronary artery disease in Indian population.

Authors:  Thiruvelselvan Ponnusamy; Srikanth K Venkatachala; Manjunatha Ramanjappa; Vijay V Kakkar; Lakshmi A Mundkur
Journal:  Heart Asia       Date:  2018-06-26

10.  Mucosal tolerance to a combination of ApoB and HSP60 peptides controls plaque progression and stabilizes vulnerable plaque in Apob(tm2Sgy)Ldlr(tm1Her)/J mice.

Authors:  Lakshmi Mundkur; Rupak Mukhopadhyay; Sonia Samson; Meenakshi Varma; Dnyaneswar Kale; Daxin Chen; Sneha Shivaprasad; Hemapriya Sivanandan; Vinod Soman; Xinjie Lu; Vijay V Kakkar
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.